Podcasts about uc san diego

Please join my mailing list here

Niki and Mike talked to Daniele Micciancio who is a professor at UC San Diego. He's been using Haskell for 20 years, and works in lattice cryptography. We talked to him about how he got into Haskell, using Haskell for teaching theoretical computer science and of course for his research and the role type systems and comonads could play in the design of cryptographic algorithms. Along the way, he gave an accessible introduction to post-quantum cryptography which we really enjoyed. We hope you do, too. 

Frank Silva talks with writer and educator Eduardo Corvera about the power of reading, writing, and the humanities. They explore how stories help us understand ourselves and the world around us. Corvera shares insights on teaching, the writing process, and why being honest and curious is essential for young writers. It's a thoughtful and inspiring conversation about creativity, literature, and finding your own voice. Series: "Education Channel" [Humanities] [Education] [Show ID: 40620]

Frank Silva talks with writer and educator Eduardo Corvera about the power of reading, writing, and the humanities. They explore how stories help us understand ourselves and the world around us. Corvera shares insights on teaching, the writing process, and why being honest and curious is essential for young writers. It's a thoughtful and inspiring conversation about creativity, literature, and finding your own voice. Series: "Education Channel" [Humanities] [Education] [Show ID: 40620]

Frank Silva talks with writer and educator Eduardo Corvera about the power of reading, writing, and the humanities. They explore how stories help us understand ourselves and the world around us. Corvera shares insights on teaching, the writing process, and why being honest and curious is essential for young writers. It's a thoughtful and inspiring conversation about creativity, literature, and finding your own voice. Series: "Education Channel" [Humanities] [Education] [Show ID: 40620]

Frank Silva talks with writer and educator Eduardo Corvera about the power of reading, writing, and the humanities. They explore how stories help us understand ourselves and the world around us. Corvera shares insights on teaching, the writing process, and why being honest and curious is essential for young writers. It's a thoughtful and inspiring conversation about creativity, literature, and finding your own voice. Series: "Education Channel" [Humanities] [Education] [Show ID: 40620]

Frank Silva talks with writer and educator Eduardo Corvera about the power of reading, writing, and the humanities. They explore how stories help us understand ourselves and the world around us. Corvera shares insights on teaching, the writing process, and why being honest and curious is essential for young writers. It's a thoughtful and inspiring conversation about creativity, literature, and finding your own voice. Series: "Education Channel" [Humanities] [Education] [Show ID: 40620]

Dr. Allison Zibelli and Dr. Rebecca Shatsky discuss advances in breast cancer research that were presented at the 2025 ASCO Annual Meeting, including a potential new standard of care for HER2+ breast cancer, the future of ER+ breast cancer management, and innovations in triple negative breast cancer therapy. Transcript Dr. Allison Zibelli: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Allison Zibelli, your guest host of the podcast today. I'm an associate professor of medicine and a breast medical oncologist at the Sidney Kimmel Comprehensive Cancer Center at Jefferson Health. There was a substantial amount of exciting breast cancer data presented at the 2025 ASCO Annual Meeting, and I'm delighted to be joined by Dr. Rebecca Shatsky today to discuss some of these key advancements. Dr. Shatsky is an associate professor of medicine at UC San Diego and the head of breast medical oncology at the UC San Diego Health Moores Cancer Center, where she also serves as the director of the Breast Cancer Clinical Trials Program and the Inflammatory and Triple-Negative Breast Cancer Program.  Our full disclosures are available in the transcript of this episode. Dr. Shatsky, it's great to have you on the podcast today. Dr. Rebecca Shatsky: Thanks, Dr. Zibelli. It's wonderful to be here. Dr. Allison Zibelli: So, we're starting with DESTINY-Breast09, which was trastuzumab deruxtecan and pertuzumab versus our more standard regimen of taxane, trastuzumab pertuzumab for first-line treatment of metastatic HER2-positive breast cancer. Could you tell us a little bit about the study? Dr. Rebecca Shatsky: Yeah, absolutely. So, this was a long-awaited study. When T-DXd, or trastuzumab deruxtecan, really hit the market, a lot of these DESTINY-Breast trials were started around the same time. Now, this was a global, randomized, phase 3 study presented by Dr. Sara Tolaney from the Dana-Farber Cancer Institute of Harvard in Boston. It was assessing essentially T-DXd in the first-line setting for metastatic HER2-positive breast cancer in addition to pertuzumab. And that was randomized against our standard-of-care regimen, which was established over a decade ago by the CLEOPATRA trial, and we've all been using that internationally for at least the past 10 years. So, this was a large trial, and it was one-to-one-to-one of patients getting T-DXd plus pertuzumab, T-DXd alone, or THP, which mostly is used as docetaxel and trastuzumab and pertuzumab every three weeks for six cycles. And this was in over 1,000 patients; it was 1,159 patients with metastatic HER2-positive breast cancer. This was a very interesting trial. It was looking at the use of trastuzumab deruxtecan, but patients were started on this treatment for their first-line metastatic HER2-positive breast cancer with no end date to their T-DXd. So, it was, you know, you were started on T-DXd every 3 weeks until progression. Now, CLEOPATRA is a little bit different than that, though, as we know. So, CLEOPATRA has a taxane plus trastuzumab and pertuzumab. But generally, patients drop the taxane after about six to seven cycles because, as we know, you can't be really on a taxane indefinitely. You get pretty substantial neuropathy as well as cytopenias, other things that end up happening. And so, in general, that regimen has sort of a limited time course for its chemotherapy portion, and the patients maintained after the taxane is dropped on their trastuzumab and their pertuzumab, plus or minus endocrine therapy if the investigator so desires. And the primary endpoint of the trial was progression-free survival by blinded, independent central review (BICR) in the intent-to-treat population. And then it had its other endpoints as overall survival, investigator-assessed progression-free survival, objective response rates, and duration of response, and of course, safety. As far as the results of this trial, so, I think that most of us key opinion leaders in breast oncology were expecting that this was going to be a positive trial. And it surely was. I mean, this is a really, really active drug, especially in HER2-positive disease, of course. So, the DESTINY-Breast03 data really established that, that this is a very effective treatment in HER2-positive metastatic breast cancer. And this trial really, again, showed that. So, there were 383 patients that ended up on the trastuzumab plus deruxtecan plus pertuzumab arm, and 387 got THP, the CLEOPATRA regimen. What was really interesting also to note of this before I go on to the results was that 52% of patients on this trial had de novo metastatic disease. And that's pretty unusual for any kind of metastatic breast cancer trial. It kind of shows you, though, just how aggressive this disease is, that a lot of patients, they present with de novo metastatic disease. It's also reflecting the global nature of this trial where maybe the screening efforts are a little bit less than maybe in the United States, and more patients are presenting as later stage because to have a metastatic breast cancer trial in the United States with 52% de novo metastatic disease doesn't usually happen. But regardless, the disease characteristics were pretty well matched between the two groups. 54% of the patients were triple positive, or you could say hormone-positive because whether they were PR positive or ER positive and PR negative doesn't really matter in this disease. And so, the interim data cutoff was February of this year, of 2025. So, the follow-up so far has been about 29 months, so the data is still really immature, only 38% mature for progression-free survival interim analysis. But what we saw is that T-DXd plus pertuzumab, it really improved progression-free survival. It had a hazard ratio that was pretty phenomenal at 0.56 with a confidence interval that was pretty narrow of 0.44 to 0.71. So, very highly statistically significant data here. The progression-free survival was consistent across all subgroups. Overall survival, very much immature at this time, but of course, the trend is towards an overall survival benefit for the T-DXd group. The median durable response with T-DXd plus pertuzumab exceeded 3 years. Now, importantly, though, I want to stress this, is grade 3 or above treatment-emergent adverse events occurred in both subgroups pretty equally. But there were 2 deaths in the T-DXd group due to interstitial lung disease. And there was a 12.1% adjudicated drug-induced interstitial lung disease/pneumonitis event rate in the T-DXd group and only 1%, and it was grade 1-2, in the THP group. So, that's really the caveat of this therapy, is we know that a percentage of patients are going to get interstitial lung disease, and that some may have very serious adverse events from it. So, that's always something I keep in the back of my mind when I treat patients with T-DXd. And so, overall, the conclusions of the trial were pretty much a slam dunk. T-DXd plus pertuzumab, it had a highly statistically significant and clinically meaningful improvement in progression-free survival versus the CLEOPATRA regimen. And that was across all subgroups for first-line metastatic HER2-positive breast cancer here. And so, yeah, the data was pretty impressive. Just to go into the overall response rate, because that's always super important as well, you had 85.1% of patients having a confirmed overall RECIST response rate in the T-DXd plus pertuzumab group and a 78.6 in the CLEOPATRA group. The complete CR rate, complete response was 15.1% in the T-DXd group and 8.5 in the CLEOPATRA regimen. And it was really an effective regimen in this group, of course. Dr. Allison Zibelli: So, the investigators say at the end of their abstract that this is the new standard of care. Would you agree with that statement? Dr. Rebecca Shatsky: Yeah, that was a bold statement to make because I would say in the United States, not necessarily at the moment because the quality of life here, you have to think really hard about. Because one thing that's really important about the DESTINY-Breast09 data is that this was very much an international trial, and in many of the countries where patients enrolled on this, they were not able to access T-DXd off trial. And so, for them, this means T-DXd now or potentially never. And so, that is a really big difference whereas internationally, that may mean standard of care. However, in the US, patients have no issues accessing T-DXd in the second- or third-line settings. And right now, it's the standard of care in the second line in the United States, with all patients basically getting this second-line therapy except for some unique patients where they may be doing a PATINA trial regimen, which we saw at San Antonio Breast Cancer in 2024 of the triple-positive patients getting hormonal therapy plus palbociclib, which had a really great durable response. That was super impressive as well. Or there is the patient that the investigator can pick KADCYLA because the patient really wants to preserve their hair or maybe it's more indolent disease. But the quality of life on T-DXd indefinitely in the first-line setting is a big deal because, again, that CLEOPATRA regimen allows patients to drop their chemotherapy component about five to six months in. And with this, you're on a drug that feels very chemo-heavy indefinitely. And so, I think there's a lot more to investigate as far as what we're going to do with this data in the United States because it's a lot to commit a patient in the first-line metastatic setting. These de novo metastatic patients, some of them may be cured, honestly, on the HER2-targeting regimen. That's something we see these days. Dr. Allison Zibelli: So, very interesting trial. I'm sure we'll be talking about this for a long time.  So, let's move on to SERENA-6, which was, I thought, a very interesting trial. This trial took patients with ER positive, advanced breast cancer after six months on an AI (aromatase inhibitor) and a CDK4/6 inhibitor. They did ctDNA every two to three months, and when they saw an ESR1 mutation emerge, they changed half of the patients to camizestrant plus CDK4/6 and kept the other half on the AI plus CDK4/6. Can you talk about that trial a little bit, please? Dr. Rebecca Shatsky: Yeah, so this was a big trial at ASCO25. This was presented as a Plenary Session. So, this was camizestrant plus a CDK4/6 inhibitor, and it could have been any of the three, so palbo, ribo, or abemaciclib in the first-line metastatic hormone-positive population, and patients were on an AI with that. They were, interestingly, tested by ctDNA at baseline to see if they had an ESR1 mutation. So, that was an interesting feature of this trial. But patients had to have already been on their CDK4/6 inhibitor plus AI for at least 6 months to enroll. And then, as you mentioned, they got ctDNA testing every 2 to 3 months. This was also a phase 3, double-blind, international trial. And I do want to highlight again, international here, because that's important when we're considering some of this data in the U.S. because it influences some of the results. So, this was presented by Dr. Nick Turner of the Royal Marsden in the UK. So, just a little bit of background for our listeners on ESR1 mutations and why they're important. This is the most common, basically, acquired resistance mutation to patients being treated with aromatase inhibitors. We know that treatment with aromatase inhibitors can induce this. It makes a conformational change in the estrogen receptor that makes the estrogen receptor constitutively active, which allows the cell to signal despite the influence of the aromatase inhibitor to decrease the estrogen production so that the ligand binding doesn't matter as much as far as the cell signaling and transcription is concerned. And camizestrant, you know, as an oral SERD, just to explain that a little bit too; these are estrogen receptor degraders. The first-in-class of a selective estrogen receptor degrader to make it to market was fulvestrant. And that's really been our standard-of-care estrogen degrader for the past 25 years, almost 25 years. And so, a lot of us are just looking for some of these oral SERDs to replace that. But regardless, they do tend to work in the ESR1-mutated population. And we know that patients on aromatase inhibitors, the estimates of patients developing an ESR1 mutation, depending on which study you look at, somewhere between 30% to 50% overall, patients will develop this mutation with hormone-positive metastatic breast cancer. There is a small percentage of patients that have these at baseline without even treatment of an aromatase inhibitor. The estimates of that are somewhere between 0.5 and up to 5%, depending on the trial you look at and the population. But regardless, there is a chance someone on their CDK4/6 inhibitor plus AI at 6 months' time course could have had an ESR1 mutation at that time. But anyway, so they got this ctDNA every 2 to 3 months, and once they were found to develop an ESR1 mutation, the patients were then switched to the oral SERD. AstraZeneca's version of the oral SERD is camizestrant, 75 mg daily. And then their type of CDK4/6 inhibitor was maintained, so they didn't switch the brand of their CDK4/6 inhibitor, importantly. And that was looked at then for progression-free survival, but these were patients with measurable disease by RECIST version 1.1. And the data cut off here was November of 2024. This was a big trial, you know, and I think that that's influential here because this was 3,256 patients, and that's a lot of patients. So, they were all eligible. And then 315 patients ended up being randomized to switch to camizestrant upon presence of that ESR1 mutation. So, that was 157 patients. And then the other half, so they were randomized 1:1, they continued on their AI without switching to an oral SERD. That was 158 patients. They were matched pretty well. And so, their baseline characteristics, you know, the two subgroups was good. But this was highly statistically significant data. I'm not going to diminish that in any way. Your hazard ratio was 0.44. Highly statistically significant confidence intervals. And you had a median progression-free survival in those that switched to camizestrant of 16 months, and then the non-switchers was 9.2 months. So, the progression-free survival benefit there was also consistent across the subgroups. And so, you had at 12 months, the PFS rate was 60.7% for the non-treatment group and 33.4% in the treatment group. What's interesting, though, is we don't have overall survival data. This is really immature, only 12% mature as far as overall survival. And again, because this was an international trial and patients in other countries right now do not have the access to oral SERDs that the United States does, the crossover rate, they were not allowed to crossover, and so, a very few patients, when we look at progression-free survival 2 and ultimately overall survival, were able to access an oral SERD in the off-trial here and in the non-treatment group. And so, that's really important as far as we look at these results. Adverse events were pretty minimal. These are very safe drugs, camizestrant and all the other oral SERDs. They have some mild toxicities. Camizestrant is known for something weird, which is called photopsia, which is some flashing lights in the periphery of the eye, but it doesn't seem to have any serious clinical significance that we know of. It has a little bit of bradycardia, but it's otherwise really well tolerated. You know, I hate to say that because that's very subjective, right? I'm not the one taking the drug. But it doesn't have any serious adverse events that would cause discontinuation. And that's really what we saw in the trial. The discontinuation rates were really low. But overall, I mean, this was a positive trial. SERENA-6 showed that switching to camizestrant at the first sign of an ESR1 mutation on CDK4/6 inhibitor plus AI improved progression-free survival. That's all we can really say from it right now. Dr. Allison Zibelli: So, let's move on to ASCENT-04, which was a bit more straightforward. Sacituzumab govitecan plus pembrolizumab versus chemotherapy plus pembrolizumab in PD-L1-positive, triple-negative breast cancer. Could you talk about that study? Dr. Rebecca Shatsky: Yeah, so this was also presented by the lovely Sara Tolaney from Dana-Farber. And this study made me really excited. And maybe that's because I'm a triple-negative breast cancer person. I mean, not to say that I don't treat hundreds of patients with hormone- positive, but our unmet needs in triple negative are huge because this is a disease where you have got to throw your best available therapy at it as soon as you can to improve survival because survival is so poor in this disease. The average survival with metastatic triple-negative breast cancer in the United States is still 13-18 months, and that's terrible. And so, for full disclosure, I did have this trial open at my site. I was one of the site PIs. I'm not the global PI of the study, obviously. So, what this study was was for patients who had had at least a progression-free survival of 6 months after their curative intent therapy or de novo metastatic disease. They were PD-L1 positive as assessed by the Dako 22C3 assay of greater than or equal to a CPS score of 10. So, that's what the KEYNOTE-355 trial was based on as well. So, standard definition of PD-L1 positive in breast cancer here. And basically, these patients were randomized 1:1 to either their sacituzumab govitecan plus pembrolizumab, day 1 they got both therapies, and then day 8 just the saci, as is standard for sacituzumab. And then the other group got the KEYNOTE-355 regimen. So, that is pembrolizumab with – your options are carbogem there, paclitaxel or nab-paclitaxel. And it's up to investigator's decision which upon those they decided. They followed these patients for disease progression or unacceptable toxicity. It was really an impressive trial in my opinion because we know already that this didn't just improve progression-free survival, because survival is so poor in this disease, of course, we know that it improved overall survival. It's trending towards that very much, and I think that's going to be shown immediately. And then the objective response rates were better, which is key in this disease because in the first-line setting, you've got a lot of people who, especially your relapsed TNBC that don't respond to anything. And you lose a ton of patients even in the first-line setting in this disease. And so, this was 222 patients to chemotherapy and pembro and 221 to sacituzumab plus pembro. Median follow-up has only been 14 months, so it's still super early here. Hazard ratio so far of progression-free survival is 0.65, highly statistically significant, narrow confidence intervals. And so, the median duration of response here for the saci group was 16.5 months versus 9.2 months. So, you're getting a 7-month progression-free survival benefit here, which in triple negative is pretty fantastic. I mean, this reminds me of when we saw the ASCENT data originally come out for sacituzumab, and we were all just so happy that we had this tool now that doubled progression-free and overall survival and made such a difference in this really horrible disease where patients do poorly. So, OS is technically immature here, but it's really trending very heavily towards improvement in overall survival. Importantly, the treatment-related adverse events in this, I mean, we know sacituzumab causes neutropenia, people who are experienced with this drug know how to manage it at this point. There wasn't any really unexpected treatment-related adverse events. You get some people with sacituzumab who have diarrhea. It's usually pretty manageable with some Imodium. So, it was cytopenias predominantly in this disease in this population that were highlighted as far as adverse events. But I'm going to be honest, like I was surprised that this wasn't the plenary over the SERENA-6 data because this, in my mind, there we have a practice-changing trial. I will immediately be trying to use this in my PD-L1 population because, to be honest, as a triple-negative breast cancer clinical specialist, when I get a patient with metastatic triple-negative breast cancer who's PD-L1 positive, I think, "Oh, thank God," because we know that part of the disease just does better in general. But now I have something that really could give them a durable response for much longer than I ever thought possible when I started really heavily treating this disease. And so, this was immediately practice-changing for me. Dr. Allison Zibelli: I think that it's pretty clear that this is at least an option, if not the option, for this group of patients. Dr. Rebecca Shatsky: Yeah, the duration of responses here was – it's just really important because, I mean, I do think this will make people live longer. Dr. Allison Zibelli: So, moving on to the final study that we're going to discuss today, neoCARHP (LBA500), which was neoadjuvant taxane plus trastuzumab, pertuzumab, plus or minus carbo(platin) in HER2-positive early breast cancer. I think this is a study a lot of us have been waiting for. What was the design and the results of this trial? Dr. Rebecca Shatsky: I was really excited about this as well because I'm one of those people that was waiting for this. This is a Chinese trial, so that is something to take note of. It wasn't an international trial, but it was a de-escalation trial which had become really popular in HER2-positive therapy because we know that we're overtreating HER2-positive breast cancer in a lot of patients. A lot of patients we're throwing the kitchen sink at it when maybe that is not necessary, and we can really de-escalate and try to personalize therapy a little bit better because these patients tend to do well. So, the standard of care, of course, in HER2-positive curative intent breast cancer with tumors that are greater than 2 cm is to give them the TCHP regimen, which is docetaxel, carboplatin, trastuzumab, and pertuzumab. And that was sort of established by several trials in the NeoSphere trial, and now it's been repeated in a lot of different studies as well. And so, that's really the standard of care that most people in the United States use for HER2-positive curative intent breast cancer. This was a trial to de-escalate the carboplatin, which I was super excited about because many of us who treat this disease a lot think carbo is the least important part of the therapy you're giving there. We don't really know that it's necessary. We've just been doing it for a long time, and we know that it adds a significant amount of toxicity. It causes thrombocytopenia, it causes severe nausea, really bad cytopenias that can be difficult in the last few cycles of this to manage. So, this trial was created. It randomized patients one to one with stage 2 and 3 HER2-positive breast cancer to either get THP, a taxane, pertuzumab, trastuzumab, similar to the what we do in first-line metastatic HER2-positive versus the whole TCHP with a carboplatin AUC of 6, which is what's pretty standard. And it was a non-inferiority trial, so important there. It wasn't to establish superiority of this regimen, which none of us, I think, were looking for it to. And it was a modified intent-to-treat population. And so, all patients got at least one cycle of this to be assessed as a standard for an intent-to-treat trial. And so, they assumed a pCR rate of about 62.8% for both groups. And, of course, it included both HER2-positive triple positives and ER negatives, which are, you know, a bit different diseases, to be honest, but we all kind of categorize them and treat them the same. And so, this trial was powered appropriately to detect a non-inferiority difference. And so, we had about 380 patients treated on both arms, and there was an absolute difference of only 1.8% of those treated with carbo versus those without. Which was fantastic because you really realized that de-escalation here may be something we can really do. And so, the patients who got, of course, the taxane regimen had fewer adverse events. They had way fewer grade 3 and 4 adverse events than the THP group. No treatment-associated deaths occur, which is pretty standard for- this is a pretty safe regimen, but it causes a lot of hospitalizations due to diarrhea, due to cytopenias, and neutropenic fever, of course. And so, I thought that this was something that I could potentially enact, you know, and be practice-changing. It's hard to say that when it's a trial that was only done in China, so it's not necessarily the United States population always. But I think for patients moving forward, especially those with, say, a 2.5 cm tumor, you know, node negative, those, I'd feel pretty comfortable not giving them the carboplatin here. Notes that I want to make about this population is that the majority were stage 2 and not stage 3. They weren't necessarily your inflammatory HER2-positive breast cancer patients. And that the taxane that was utilized in the trial is a little different than what we use in the United States. The patients were allowed to get nab-paclitaxel, which we don't have FDA approval for in the first-line curative intent setting for HER2-positive breast cancer in the United States. So, a lot of them got abraxane, and then they also got paclitaxel. We tend to use docetaxel every 3 weeks in the United States. So, just to point out that difference. We don't really know if that's important or not, but it's just a little bit different to the population we standardly treat. Dr. Allison Zibelli: So, are there patients that you would still give TCHP to? Dr. Rebecca Shatsky: Yeah, great question. I've been asked that a lot in the past like week since ASCO. I'd say in my inflammatory breast cancer patients, that's a group I do tend to sometimes throw the kitchen sink at. Now, I don't actually use AC in those because I know that that was the concern, but I think the TRAIN-2 trial really showed us you don't need to use Adriamycin in HER2-positive disease unless it's like refractory. So, I don't know that I would throw this on my stage 3C or inflammatory breast cancer patients yet because the majority of this were not stage 3. So, in your really highly lymph node positive patients, I'm a little bit hesitant to de-escalate them from the start. This is more of a like, if there's serious toxicity concerns, dropping carbo is absolutely fine here. Dr. Allison Zibelli: All right, great.  Thank you, Dr. Shatsky, for sharing your valuable insights with us on the ASCO Daily News Podcast today. Dr. Rebecca Shatsky: Thanks so much, Dr. Zibelli and ASCO Daily News. I really want to thank you for inviting me to talk about this today. It was really fun, and I hope you find my opinions on some of this valuable. And so, I just want to thank everybody and my listeners as well. Dr. Allison Zibelli: And thank you to our listeners for joining us today. You'll find the links to all the abstracts discussed today in the transcript of this episode. Finally, if you like this podcast and you learn things from it, please take a moment to rate, review, and describe because it helps other people find us wherever you get your podcasts. Thank you again. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers Dr. Allison Zibelli Dr. Rebecca Shatsky @Dr_RShatsky Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn   Disclosures: Dr. Allison Zibelli: No relationships to disclose Dr. Rebecca Shatsky: Consulting or Advisory Role: Stemline, Astra Zeneca, Endeavor BioMedicines, Lilly, Novartis, TEMPUS, Guardant Health, Daiichi Sankyo/Astra Zeneca, Pfizer Research Funding (Inst.): OBI Pharma, Astra Zeneca, Greenwich LifeSciences, Briacell, Gilead, OnKure, QuantumLeap Health, Stemline Therapeutics, Regor Therapeutics, Greenwich LifeSciences, Alterome Therapeutics  

In this thoughtful presentation, Professor Emerita Laura Rendón, Ph.D., of the University of Texas - San Antonio, talks about her advocacy work in student preparation, access, and success. Her research has been published in education research journals and informed policies and practices within higher education that have transformed the lives of students. As the creator of the Validation Theory, she has helped redefine how we support and uplift students. Rendón is joined by Carolyn Sandoval, Ph.D., Senior Director of Instruction, UC San Diego, for a further discussion on how to advance student learning. [Education] [Show ID: 40679]

In this thoughtful presentation, Professor Emerita Laura Rendón, Ph.D., of the University of Texas - San Antonio, talks about her advocacy work in student preparation, access, and success. Her research has been published in education research journals and informed policies and practices within higher education that have transformed the lives of students. As the creator of the Validation Theory, she has helped redefine how we support and uplift students. Rendón is joined by Carolyn Sandoval, Ph.D., Senior Director of Instruction, UC San Diego, for a further discussion on how to advance student learning. [Education] [Show ID: 40679]

"Craft does not define size... craft is defined by technique, innovation, and quality." This insight from Ishan Varshnei challenges the common misconception that craft businesses can't scale. His scientific approach to brewing has proven that maintaining artisanal quality while achieving commercial scale is not just possible, but profitable. Ishan Varshnei is the CEO of Latambarcem Brewers, housing craft beer brand Maka Di and functional beverage brand Borécha. He has built a dual-brand beverage empire generating ₹30 crores annual run rate, with 80 lakhs monthly revenue from kombucha alone and 400% projected growth this year. After bootstrapping with ₹25 crores family funding for 4 years, he raised ₹12.5 crores in Pre-Series A and is targeting ₹500 crores revenue within 5 years. Ishan holds advanced degrees in Nanoengineering from UC San Diego and Materials Science from Columbia University, and previously worked as a Business Analyst at a Blackstone portfolio fund. Key Insights from the Conversation:

As a listener of TOE you can get a special 20% off discount to The Economist and all it has to offer! Visit https://www.economist.com/toe Are the laws of physics governing forces or elegant summaries? In this deep and often humorous debate, Barry Loewer of Rutgers and Eddy Chen of UC San Diego clash over the very nature of physical reality. Are the laws of nature real, mind independent constraints that shape what's possible or are they human made descriptions of observed patterns? Together they explore metaphysics, causation, probability, and whether the universe is truly ruled by anything at all. A must watch for anyone questioning the foundations of science itself. Join My New Substack (Personal Writings): https://curtjaimungal.substack.com Listen on Spotify: https://open.spotify.com/show/4gL14b92xAErofYQA7bU4e Timestamps: 00:00 The Nature of Physical Reality 42:28 The Circularity of Scientific Understanding 1:05:44 Reality Explored 1:08:28 Describing Human Experience 1:10:10 The Role of Science 1:10:58 Understanding Motion and Laws 1:12:19 The Nature of Laws 1:14:55 Possible Worlds in Philosophy 1:18:05 Configuration Space Debate 1:21:10 Quantum Mechanics and Reality 1:22:50 Metaphysical Necessity 1:27:13 The Nature of Free Will 1:30:14 Bridging Philosophy and Science 1:32:05 Constraints and Freedom 1:34:57 Philosophical Disputes 1:39:08 The Journey of Learning 2:05:16 Teaching and Learning Dynamics 2:07:23 Closing Reflections Links Mentioned: •⁠ ⁠Barry's published papers: https://scholar.google.com/citations?user=n_RTOwO00oEC&hl=en •⁠ ⁠Eddy's published papers: https://arxiv.org/a/chen_e_1.html •⁠ ⁠Neil Turok on TOE: https://youtu.be/ZUp9x44N3uE •⁠ ⁠Greg Chaitin on TOE: https://youtu.be/zMPnrNL3zsE •⁠ ⁠Leonard Susskind on TOE: https://youtu.be/2p_Hlm6aCok •⁠ ⁠Emily Adlam on TOE: https://youtu.be/6I2OhmVWLMs •⁠ ⁠Laws of Nature and Chances (book): https://www.amazon.com/Laws-Nature-Chances-Breathes-Equations/dp/0198907699 •⁠ ⁠Laws of Physics (book): https://www.amazon.com/Laws-Physics-Elements-Philosophy/dp/100901272X/ref=sr_1_1?crid=1CHA72RYFUOI8&dib=eyJ2IjoiMSJ9.OjkhTXRzZw_SWTMFZp8dUtREsTxacKuwg03AsLUUp6qLCuygS74CtEgujWl7wMvVEt-ErFEz-CfFLiiXTmuUCwKq0TW4WLFIA3DIhDNVaV4.gRuqaZldjUa8Kv_j1ew-CfZGQqtdt00X55fyMZ9NGD4&dib_tag=se&keywords=eddy+chen&qid=1749667626&s=books&sprefix=eddy+chen%2Cstripbooks%2C128&sr=1-1 •⁠ ⁠On the Plurality of Worlds (book): https://www.amazon.com/Plurality-Worlds-David-K-Lewis/dp/0631224262 •⁠ ⁠Tim Maudlin on TOE: https://youtu.be/fU1bs5o3nss •⁠ ⁠Tim Maudlin and Tim Palmer on TOE: https://youtu.be/883R3JlZHXE •⁠ ⁠How Physics Makes Us Free (book): https://www.amazon.com/How-Physics-Makes-Us-Free/dp/0190269448 •⁠ ⁠From Time Asymmetry to Quantum Entanglement (paper): https://arxiv.org/pdf/2006.05029 •⁠ ⁠Jacob Barandes on TOE: https://youtu.be/7oWip00iXbo •⁠ ⁠Realism with a Human Face (book): https://www.amazon.com/Realism-Human-Face-Hilary-Putnam/dp/0674749456 •⁠ ⁠Causation and Laws of Nature in Early Modern Philosophy (book): https://www.amazon.com/Causation-Nature-Early-Modern-Philosophy/dp/0199664684/ref=tmm_pap_swatch_0 •⁠ ⁠The Maniac (book): https://www.amazon.com/MANIAC-Benjamin-Labatut/dp/0593654471 •⁠ ⁠When We Cease to Understand the World (book): https://www.amazon.com/When-We-Cease-Understand-World/dp/1681375664 •⁠ ⁠Eddy's paper on time and nature: https://arxiv.org/pdf/2109.09226 SUPPORT: - Become a YouTube Member (Early Access Videos): https://www.youtube.com/channel/UCdWIQh9DGG6uhJk8eyIFl1w/join - Support me on Patreon: https://patreon.com/curtjaimungal - Support me on Crypto: https://commerce.coinbase.com/checkout/de803625-87d3-4300-ab6d-85d4258834a9 - Support me on PayPal: https://www.paypal.com/donate?hosted_button_id=XUBHNMFXUX5S4 SOCIALS: - Twitter: https://twitter.com/TOEwithCurt - Discord Invite: https://discord.com/invite/kBcnfNVwqs #science Learn more about your ad choices. Visit megaphone.fm/adchoices

Police estimate at least 60,000 people showed up to a No Kings Demonstration at Waterfront Park yesterday. UC San Diego and UC San Diego Health say they won't be participating in San Diego Pride Festival events this year over concerns with the headline performer. Tomorrow i the last day for South Bay San Diegans to register to vote in the special general election to fill the vacant seat in the County's first district.   What You Need To Know To Start Your Sunday. 

The San Diego chapter of the Council on American-Islamic Relations and immigrant rights groups rallied in front of San Diego International Airport protesting President Trump's latest travel ban. Plus, advocates are renewing calls for San Diego police to end a controversial surveillance program. And, a UC San Diego researcher says migration to the U.S. is not a zero-sum game and the data reveals many benefits for all countries involved.

In this profound episode of Parallax, Dr Ankur Kalra welcomes Dr Pam Taub, Professor of Medicine and Director of Preventive Cardiology at UC San Diego, for an enlightening conversation about integrating spirituality, purpose, and scientific curiosity in cardiovascular practice. Dr Taub shares her unique philosophical foundation, shaped by exposure to diverse religions in South India. This experience fostered her belief that all faiths fundamentally center on being a good person and serving others. She explores how this spiritual perspective transforms medicine from a profession into a sacred calling, where patient interactions become profound privileges that fuel her desire to make meaningful impact beyond individual achievements. The episode highlights Dr Taub's groundbreaking work with POTS (Postural Orthostatic Tachycardia Syndrome), demonstrating how scientific curiosity serves as a spiritual path. Her research journey—from recognizing misdiagnosed conditions to conducting the first clinical trial for ivabradine in POTS—exemplifies how deeper questioning and evidence-based inquiry can transform patient lives on a broader scale. The episode also explores Dr Taub's research on time-restricted eating, connecting modern scientific evidence to fasting practices across many faiths. Questions and comments can be sent to "podcast@radcliffe-group.com" and may be answered by Ankur in the next episode. Host: @AnkurKalraMD and produced by: @RadcliffeCardio Parallax is Ranked in the Top 100 Health Science Podcasts (#48) by Million Podcasts.

In this wide-ranging conversation, we explore the implications of planetary-scale computation with Benjamin Bratton, Director of the Antikythera program at the Berggruen Institute and Professor at UC San Diego. Benjamin describes his interdisciplinary work as appearing like a "platypus" to others—an odd creature combining seemingly incompatible parts that somehow works as a coherent whole.At the heart of our discussion is Benjamin's framework for understanding how computational technology literally evolves, not metaphorically but through the same mechanisms that drive biological evolution: scaffolding, symbiogenesis, niche construction, and what he calls "allopoiesis"—the process by which organisms transform their external environment to capture more energy and information.Key themes we explore:Computational Evolution: How artificial computation has become the primary mechanism for human "allopoietic virtuosity"—our ability to reshape our environment to sustain larger populationsThe Embodiment Question: Moving beyond anthropomorphic assumptions about AI embodiment to imagine synthetic intelligence with radically different spatial capabilities and sensory arrangementsAgentic Multiplication: How the explosion of AI agents (potentially reaching hundreds of billions) will fundamentally alter human agency and subjectivity, creating "parasocial relationships with ourselves"Planetary Intelligence: Understanding Earth itself as having evolved a computational sensory layer through satellites, fiber optic networks, and distributed sensing systemsThe Paradox of Intelligence: Whether complex intelligence is ultimately evolutionarily adaptive, given that our computational enlightenment has revealed our own role in potentially destroying the substrate we depend onBenjamin challenges us to think beyond conventional categories of life, intelligence, and technology, arguing that these distinctions are converging into something more fundamental. As he puts it: "Agency precedes subjectivity"—we've been transforming our world at terraforming scales long before we were conscious of doing so.The conversation culminates in what Benjamin calls "the paradox of intelligence": What are the preconditions necessary to ensure that complex intelligence remains evolutionarily adaptive rather than self-destructive? As he notes, we became aware of our terraforming-scale agency precisely at the moment we discovered it might be destroying the substrate we depend on. It's a question that becomes increasingly urgent as we stand at the threshold of what could be either a viable planetary civilization or civilizational collapse—what Benjamin sees as requiring us to fundamentally rethink "what planetary scale computation is for."About Benjamin Bratton: Benjamin Bratton is a philosopher of technology, Professor of Philosophy of Technology and Speculative Design at UC San Diego, and Director of Antikythera, a think tank researching planetary computation at the Berggruen Institute. Beginning in 2024, he also serves as Visiting Faculty Researcher at Google's Paradigms of Intelligence group, conducting fundamental research on the artificialization of intelligence.His influential book The Stack: On Software and Sovereignty (MIT Press, 2015) develops a comprehensive framework for understanding planetary computation through six modular layers: Earth, Cloud, City, Address, Interface, and User. Other recent works include Accept All Cookies (Berggruen Press), written in conjunction with his co-curation of "The Next Earth: Computation, Crisis, Cosmology" at the 2025 Venice Architecture Biennale, and The Terraforming (Strelka), a manifesto arguing for embracing anthropogenic artificiality to compose a planet sustaining diverse life.

Please join my mailing list here

Sam Aros-Mitchell (he/him) is an enrolled member of the Texas Band of Yaqui Indians and an interdisciplinary artist, scholar, and educator. His work spans performance, sound, light and scenic design, choreography, and embodied writing. Rooted in Indigenous cosmologies, his practice activates performance spaces as sacred sites of transformation, remembrance, and futurity. Through embodied scholarship, he interrogates colonial histories, uplifts BIPOC artistic excellence, and envisions just futures. Aros-Mitchell holds a Ph.D. in Drama and Theatre from the joint doctoral program at UC San Diego/UC Irvine, an MFA in Dance Theatre from UC San Diego, and a BFA from UC Santa Barbara. He is a 2025 Jerome Fellow and a 2023 McKnight Dance Fellow. Recently, he produced the inaugural Macalester Native Play Festival and will produce a week-long Indigenous arts festival in Mni Sota Makoce in November 2025, supported by the Minnesota State Arts Board. As a choreographer, his works include Ania Bwia Bwia Toochia , performed at Red Eye's Works in Progress (May 2023), and Finding Sentience , performed by Semaphore Dance Repertory (November 2023). Since 2017, Aros-Mitchell has collaborated with Rosy Simas Danse as a performer, teacher, and community engagement organizer, appearing in Skins (2018), Weave (2019), Simas' short film yödoishëndahgwa'geh (2021), and she lives on the road to war (2022–2024). He has also performed in Prairie/Concrete with Aniccha Arts (2023), Inner Blades of Grass (Soft), Inner Blades of Grass (Cured), Inner Blades of Grass (Bruised by the Weather) by Alutiiq/Sugpiaq multidisciplinary artist Tanya Lukin Linklater (2024), and Morgan Thorson's Untitled Night (2024).For more information, visit www.samarosmitchell.com

In this season of WorkLife, we're pairing each of our regular episodes with a companion interview to do a deeper dive into the topic. This is the companion for our episode on the secrets of a great apology. Michael McCullough is a psychology professor at UC San Diego and a pioneer in the study of forgiveness, gratitude, and empathy—he finds that although forgiveness is important, it isn't always the answer to conflict. Michael and Adam discuss why humans evolved to forgive, examine what causes people to hold grudges, and settle last episode's debate about whether it's appropriate to ask for forgiveness. Host: Adam Grant (Instagram: @adamgrant | LinkedIn: @adammgrant | Website: adamgrant.net/) Guest: Michael McCullough (Website: michael-mccullough.com/) Linkspsychology.ucsd.edu/people/profiles/mmccullough.htmlSubscribe to TED Instagram: @tedYouTube: @TEDTikTok: @tedtoksLinkedIn: @ted-conferencesWebsite: ted.comPodcasts: ted.com/podcastsFor the full text transcript, visit ted.com/podcasts/worklife/worklife-with-adam-grant-transcriptsWant to help shape TED's shows going forward? Fill out our survey! Hosted on Acast. See acast.com/privacy for more information.

In this season of WorkLife, we're pairing each of our regular episodes with a companion interview to do a deeper dive into the topic. This is the companion for our episode on the secrets of a great apology. Michael McCullough is a psychology professor at UC San Diego and a pioneer in the study of forgiveness, gratitude, and empathy—he finds that although forgiveness is important, it isn't always the answer to conflict. Michael and Adam discuss why humans evolved to forgive, examine what causes people to hold grudges, and settle last episode's debate about whether it's appropriate to ask for forgiveness. Host: Adam Grant (Instagram: @adamgrant | LinkedIn: @adammgrant | Website: adamgrant.net/) Guest: Michael McCullough (Website: michael-mccullough.com/) Linkspsychology.ucsd.edu/people/profiles/mmccullough.htmlSubscribe to TED Instagram: @tedYouTube: @TEDTikTok: @tedtoksLinkedIn: @ted-conferencesWebsite: ted.comPodcasts: ted.com/podcastsFor the full text transcript, visit ted.com/podcasts/rethinking-with-adam-grant-transcriptsWant to help shape TED's shows going forward? Fill out our survey! Hosted on Acast. See acast.com/privacy for more information.

Send us a textIn this episode of Causes or Cures, we explore insights into brain health and longevity with NYT bestselling author and neurologist Dr. Dale Bredesen.Dr. Bredesen explains why he believes cognitive decline is not an inevitable part of aging and outlines six biological processes he identifies as impacting brain aging. He also shares practical tools he recommends for assessing how well your mind is functioning. We discuss the alarming rise in early-onset dementia among people in their 30s and 40s and the potential causes behind this increase. Dr. Bredesen also talks about the links between COVID, sugar intake, and dementia risk. He offers science-based advice on diet, sleep, and lifestyle strategies that support an ageless brain.Additionally, Dr. Bredesen addresses how the for-profit healthcare system can hinder Alzheimer's management and shares his comprehensive ReCODE Protocol™, which he presents as a promising approach to preventing and potentially reversing cognitive decline, though it has sparked passionate discussions and differing opinions in the Alzheimer's and broader medical communities.About Dr. Dale Bredesen Dr. Bredesen is an internationally recognized expert in neurodegenerative diseases and the author of The Ageless Brain and The End of Alzheimer's Disease. He earned his M.D. from Duke University Medical Center, completed his neurology residency at UCSF, and was an NIH Postdoctoral Fellow in Nobel laureate Stanley Prusiner's laboratory. He has held faculty positions at UCSF, UCLA, and UC San Diego, and was founding President and CEO of the Buck Institute for Research on Aging. Dr. Bredesen's pioneering research has led to innovative treatments and the development of the ReCODE Protocol™, offering new hope in the fight against Alzheimer's disease.You can contact Dr. Eeks at bloomingwellness.com.Follow Eeks on Instagram here.Or Facebook here.Or X.On Youtube.Or TikTok.SUBSCRIBE to her monthly newsletter here.Support the show

A new UC San Diego study finds harmful chemicals in the air. And insurance claims after last week's plane crash could get complicated. Then, a conversation about the impacts of broad government austerity on communities. Also, Voice of San Diego's Scott Lewis says the city's budget fight could be setting up a serious show-down between the city council and mayor. Finally, San Diego Unified is looking for student and family feedback on a proposed policy that would further limit students' access to their cell phones at school.

On this episode, I chat with Victor Shih about all things China. We discuss China's massive local debt crisis, the CCP's views on AI, what happens after Xi, and more.Victor Shih is an expert on the Chinese political system, as well as their banking and fiscal policies, and he has amassed more biographical data on the Chinese elite than anyone else in the world. He teaches at UC San Diego, where he also directs the 21st Century China Center.Watch on YouTube; listen on Apple Podcasts or Spotify.Sponsors* Scale is building the infrastructure for smarter, safer AI. In addition to their Data Foundry, they just released Scale Evaluation, a tool that diagnoses model limitations. Learn how Scale can help you push the frontier at scale.com/dwarkesh.* WorkOS is how top AI companies ship critical enterprise features without burning months of engineering time. If you need features like SSO, audit logs, or user provisioning, head to workos.com.To sponsor a future episode, visit dwarkesh.com/advertise.Timestamps(00:00:00) – Is China more decentralized than the US?(00:03:16) – How the Politburo Standing Committee makes decisions(00:21:07) – Xi's right hand man in charge of AGI(00:35:37) – DeepSeek was trained to track CCP policy(00:45:35) – Local government debt crisis(00:50:00) – BYD, CATL, & financial repression(00:58:12) – How corruption leads to overbuilding(01:10:46) – Probability of Taiwan invasion(01:18:56) – Succession after Xi(01:25:10) – Future growth forecasts Get full access to Dwarkesh Podcast at www.dwarkesh.com/subscribe

Artificial intelligence is changing who can be a computer programmer. Leo Porter, professor of computer science and engineering at the University of California San Diego, explores how. Leo Porter is a Professor of Computer Science and Engineering at UC San Diego interested in computer science education research and computer architecture. Leo co-founded the Computing Education […]

A KPBS analysis finds the new proposed ADU rules in San Diego would make it significantly more difficult to build in the city's whitest and wealthiest neighborhoods. Then, find out which issue UC San Diego researchers say has broad support among Republican and Democrat voters. Voice of San Diego's Lisa Halverstadt joins us to talk about how a fight between the city and county is endangering one successful homeless shelter. And a white actress is suing the county library for discrimination after it wouldn't allow her to portray Black civil rights icons. Finally, health violations at an El Cajon skilled nursing facility temporarily shut down its kitchen — a rare, but serious action.

Yaron Singer, Vice President of AI and Security at Cisco, co-founded a company specializing in artificial intelligence solutions, which was acquired by Cisco in 2024. They developed a firewall for artificial intelligence, a tool designed to protect AI from making critical mistakes. No matter how sophisticated AI is, errors can still happen, and these errors can have far-reaching consequences. The product is designed to detect and fix such mistakes. This technology was developed long before ChatGPT and its competitors burst onto the scene, making it the hottest industry in tech investment. Join Singer as he sits down with UC San Diego professor Mikhail Belkin to discuss his work and the continued effort to make artificial intelligence secure. Series: "Data Science Channel" [Science] [Show ID: 40265]

Yaron Singer, Vice President of AI and Security at Cisco, co-founded a company specializing in artificial intelligence solutions, which was acquired by Cisco in 2024. They developed a firewall for artificial intelligence, a tool designed to protect AI from making critical mistakes. No matter how sophisticated AI is, errors can still happen, and these errors can have far-reaching consequences. The product is designed to detect and fix such mistakes. This technology was developed long before ChatGPT and its competitors burst onto the scene, making it the hottest industry in tech investment. Join Singer as he sits down with UC San Diego professor Mikhail Belkin to discuss his work and the continued effort to make artificial intelligence secure. Series: "Data Science Channel" [Science] [Show ID: 40265]

Yaron Singer, Vice President of AI and Security at Cisco, co-founded a company specializing in artificial intelligence solutions, which was acquired by Cisco in 2024. They developed a firewall for artificial intelligence, a tool designed to protect AI from making critical mistakes. No matter how sophisticated AI is, errors can still happen, and these errors can have far-reaching consequences. The product is designed to detect and fix such mistakes. This technology was developed long before ChatGPT and its competitors burst onto the scene, making it the hottest industry in tech investment. Join Singer as he sits down with UC San Diego professor Mikhail Belkin to discuss his work and the continued effort to make artificial intelligence secure. Series: "Data Science Channel" [Science] [Show ID: 40265]

Yaron Singer, Vice President of AI and Security at Cisco, co-founded a company specializing in artificial intelligence solutions, which was acquired by Cisco in 2024. They developed a firewall for artificial intelligence, a tool designed to protect AI from making critical mistakes. No matter how sophisticated AI is, errors can still happen, and these errors can have far-reaching consequences. The product is designed to detect and fix such mistakes. This technology was developed long before ChatGPT and its competitors burst onto the scene, making it the hottest industry in tech investment. Join Singer as he sits down with UC San Diego professor Mikhail Belkin to discuss his work and the continued effort to make artificial intelligence secure. Series: "Data Science Channel" [Science] [Show ID: 40265]

UC San Diego researchers are trying to find out why women are at a higher risk for Alzheimer's disease. Plus, a KPBS investigation found out that San Diego's highest paid city employees are cops that work lots of overtime. San Diego's police chief said they plan to rein in overtime hours and spending. And a new TikTok trend is influencing San Diego Unified students to damage their school-issued Chromebooks.

In this episode of Research Renaissance, host Deborah Westphal sits down with Dr. Frank Furnari, professor of medicine at UC San Diego and co-director of the Brain Tumor Program at the Sanford Stem Cell Institute. Together, they explore one of the most aggressive and complex cancers known to medicine—glioblastoma—and the innovative tools his team is developing to study and treat it.

Gary talks about Hawaii Athletics, especially after last night's win over UC San Diego as the 'Bows are only one win away to nab a berth into the Big West Tournament with two games left, and ESPN Honolulu's play by play announcer Josh Pacheco furthers the conversation.Gary also talks NBA Playoffs with Barstool's Dan Greenburg as they pair discusses their teams facing off in Game 6 tonight between the Knicks and the Celtics.

Episode 051 | Greg Maguire, PhD is the Co-Founder of the SRM Living Foundry at UCSD in San Diego and the Co-Founder & Chief Scientific Officer of NeoGenesis, a wonderful company I talk with my patients about all the time. If you haven't yet listed to episode 047 featuring Christine Preston, that one pairs delightfully with my conversation with Dr. Maguire.Awarded a prestigious Fulbright-Fogarty Fellowship from the National Institutes of Health, Dr. Maguire managed his NIH funded laboratory at UCSD studying tissue degeneration and regeneration, and the role of stem cell released molecules (SRM) through paracrine and autocrine actions to maintain, repair, and regenerate human tissues. His NIH funded studies of systems biology and reverse engineering at UC Berkeley and stem cell biology at UC San Diego led to the development of adult stem cell-based S2RM® technology for the development of therapeutics and medical procedures.Dr. Maguire pursued his graduate training at the University of California, Berkeley, University of Houston, University of Texas, The Marine Biological Labs, Woods Hole, MA, and Cold Spring Harbor Laboratory, NY. He is a former professor of neuroscience and ophthalmology at the University of California, San Diego School of Medicine, a visiting associate professor of physiology at Keio University School of Medicine in Tokyo, Japan, visiting assistant professor of molecular neurobiology at the University of Washington, and a visiting scientist at Massachusetts General Hospital (MGH), at Harvard University.Dr. Maguire has over 100 publications and is currently working on his book entitled, “Spontaneous Stem Cell Healing”.The Above & Beyond Dermatology podcast is grateful to NeoGenesis for the great work they do and for their generous support of this episode. If you're a skin care professional and would like to learn more about helping your customers with NeoGenesis, click here to learn more. If you'd like to learn directly from the NeoGenesis team, text me at 715-391-9774 and I'll be happy to make a warm introduction.Connect with and learn from Greg Maguire & NeoGenesisLearn & Shop NeoGenesisDr. Maguire's Skin Care BlogNeoGenesis Wholesale Partnership for Medical ProfessionalsMore from Dr. Lewellis and Above & Beyond DermatologyNeed a dermatologist? Fill out this short interest form, text or call me at 715-391-9774, or email me at drlewellis@aboveandbeyondderm.com if you'd like to have a no obligation discovery call. I offer in-office visits, house calls, and virtual care in Wisconsin and virtual care in Illinois, Nebraska, and Colorado.Have an idea for a guest or want to be on the show yourself? Send me a text or email, and we'll see if it's a good fit.

Gary talks about the NBA Playoffs after his Knicks drop a game to the injured Celtics, and the Warriors getting knocked out by the Timberwolves. Gary talks about the MLB and Pete Rose with USA Today's Bob Nightengale, and more about Rainbow Baseball with Scott Robbs as the team gets ready for the series opener against UC San Diego tonight.

In the final regular season edition of Extra Innings with Rich Hill, Coach Hill joins Josh at Diamond Sports Bar and Lounge to break down the series win over Cal State Fullerton to set up a pivotal series against UC San Diego to dictate whether or not Rainbow Baseball will be represented in the inaugural Big West Tournament. Coach Hill is joined by one of his pitchers Liam O'Brien and center fielder Matt Miura, as they discuss this season of baseball and their own stories of and about Hawaii baseball.

Johns Hopkins earthquake engineer and cold-formed steel researcher Ben Schafer introduces the NHERI CFS10 project underway at the NHERI UC San Diego shake table facility. Tara Hutchinson, Schafer's co-PI on the project, is a research engineer at UC San Diego. (We will meet Hutchinson in an upcoming episode.) The CFS10 shake table experiment caps off a long-term collaboration between NSF researchers and industry. The goal: to understand seismic performance of taller cold-formed steel buildings. The structure on the shake table mimics an apartment building or hotel; it exceeds current height and system limits – which will help the team understand how far engineers can go designing for CFS structural elements, subsystems, and non-structural elements, like stairs, gas lines and sprinkler systems. The CFS10 shake table tests are slated for early June, 2025. Follow along on the UCSD live cameras: https://nheri.ucsd.edu/live-cams

Dave Marchick is the Dean of American University's Kogod School of Business and a seasoned leader with experience across the private, public, and nonprofit sectors. He spent over a decade as Managing Director at The Carlyle Group, where he served on the management committee and advanced the firm's sustainability and diversity efforts. In government, he held senior roles in both the Biden and Clinton administrations, including leadership positions at the State Department, the White House, and the Development Finance Corporation. Dave directed the Center for Presidential Transition during the 2020 cycle and later launched the Transition Lab podcast and co-authored The Peaceful Transition of Power. A dedicated advocate for civil rights and historical preservation, he has served on the boards of the Holocaust Memorial Museum and the National Park Foundation. Dave holds degrees from George Washington University, the LBJ School at UT Austin, and UC San Diego.In this conversation, we discuss:How Dean Dave Marchick is helping to infuse AI across the curriculum at American University's Kogod School of Business.The resistance and cultural shifts required to get faculty on board with AI adoption.How students are learning to prompt, critique, and collaborate with AI from their first semester (and how it's reshaping classroom dynamics).Why professionalism, communication, and negotiation are now prioritized as “skills of the future”.How Kogod is thinking about measuring the real-world impact of AI education beyond the classroom.Lessons from U.S. presidential transitions and what they reveal about leadership during critical moments.Resources:Subscribe to the AI & The Future of Work Newsletter: https://aiandwork.beehiiv.com/subscribe Connect with Dave on LinkedIn: https://www.linkedin.com/in/david-marchick/ AI fun fact article: https://www.psu.edu/news/campus-life/story/cheat-thon-contest-explores-ais-strengths-and-flaws-higher-education On what it was like to co-author a book with ChatGPT: https://podcasts.apple.com/us/podcast/bob-rogers-ai-expert-physicist-author-and-ceo-of-oii/id1476885647?i=1000606108950 Other episodes mentioned in the show:Episode with George Sivulka [Hebbia CEO]Episode with Tom Wheeler [Former FCC Chairman and author of Techlash]Episode with Chris Caren [Turnitin CEO]Read Dave Marchick's book: The Peaceful Transfer of Power: An Oral History of America's Presidential Transitions 

In a special episode recorded at the Milken Global Institute, Jeff moderates a wide-ranging panel with higher education leaders including the presidents of Dartmouth, Stanford, UC San Diego, Yeshiva University, and the CEO of ETS. The conversation explores the crises and critiques facing higher ed—from campus protests and declining public trust to research funding and economic ROI. The leaders discuss how institutions can reaffirm their missions, serve a broader public, and restore faith in the value of a degree in an era of polarization and political scrutiny.

Welcome to a fascinating journey into the limits of imagination, geometry, and scientific discovery. In this premiere episode of "The Scientists," a new series on the Into The Impossible Podcast Network, host Brian Keating—Chancellor's Distinguished Professor of Physics at UC San Diego—dives deep into the curious world of "Flatland," Edwin Abbott Abbott's mind-bending Victorian novel. But this isn't just dusty literature; it's a geometric allegory that shaped some of the greatest scientific minds, including Albert Einstein himself. Alongside surprising social commentary and a critique of rigid hierarchies, Keating unpacks the power of imagination in science, showing how boundary-pushing thinkers moved from heresy to genius. Sit back as you journey through dimensions with Brian Keating—plus a special segment from science communicator Carl Sagan—inviting you to rethink your own perspective on the universe and the unseen realities that might lie just beyond. Ready to challenge what you believe about reality? Stay curious and let's step into the impossible together. Please join my mailing list here

Welcome to the debut episode of "The Scientists," a captivating new series from the Into the Impossible Podcast Network, hosted by Brian Keating, Chancellor's Distinguished Professor of Physics at UC San Diego. Each week, Brian takes us on a journey into the extraordinary minds behind history's greatest scientific breakthroughs—not just exploring what these giants of science discovered, but delving deep into who they were, what drove their relentless curiosity, and the very human obsessions that shaped their careers and our world. If you're curious about the messy, intensely human reality behind monumental discoveries—and how these stories can reshape your worldview—tune in as we venture into the lives, the questions, and the obsessions that made science possible. Please join my mailing list here

Pradeep Khosla is the chancellor of UC San Diego and a nationally recognized voice on the evolving role of public research universities. Under his leadership, UC San Diego has doubled in size, broadened its access, and transformed from a "diamond in the rough" into a globally respected powerhouse for innovation, education, and the arts. He spearheaded the expansion of student housing—growing UC San Diego's housing program into the second largest in the nation—to make college more affordable and accessible for thousands. Chancellor Khosla brings a strategic, inclusive lens to higher ed. This Episode:  What should the modern public university look like and who should it serve? In this episode of Stop & Talk, host Grant Oliphant and co-host Crystal Page sit down with Pradeep Khosla, Chancellor of UC San Diego, to discuss the transformational growth and philosophy behind one of the nation's top public universities. Chancellor Khosla offers an expansive view on the role of public research universities in society—from economic impact to cultural integration and educational access. With a focus on abundance over scarcity, Chancellor Khosla explains how UC San Diego has evolved into a national leader in both science and the arts, investing in student housing, public transit access, and downtown engagement. He also reflects on the challenges of leading through federal uncertainty, advocating for research funding, and shaping an inclusive institution that belongs to the community it serves. Key Moments: [3:20] From Pittsburgh to La Jolla – Why Chancellor Khosla came to UC San Diego and what he saw in its untapped potential. [6:05] Elite, Not Elitist – How UC San Diego is challenging the notion that exclusivity equals excellence in higher education. [21:30] Universities as Economic Engines – Why public research institutions are essential to regional prosperity and innovation. [27:30]  Housing is Access – How UCSD is addressing affordability by building one of the largest student housing programs in the country.  [37:40] The Importance of the Arts – The value of connecting the arts to education and community Resources Mentioned in This Episode: UC San Diego Park & Market – A cultural and academic hub in downtown San Diego The Depot – UCSD's newly purchased multidisciplinary arts incubator and cultural hub in Downtown San Diego San Diego Light Rail – Connecting communities to the UCSD campus Take Action: Attend Events at Park & Market: Explore arts, lectures, and public programming in downtown SD. Visit UC San Diego: From the Birch Aquarium to campus cultural events, UCSD is open to all. Support Public Education & Research: Advocate for research funding and equitable higher ed access. Connect with the Arts: Engage with programs at The Depot and La Jolla Playhouse. Explore Philanthropy: Consider supporting educational initiatives that expand opportunity. 

Get to know Janna Aboudaher and Tean Brooks from the women's fencing team on episode 114 of Tritoncast! These fifth-year Tritons will tell us about how it took them more than six months to meet despite being teammates, and how their friendship has grown. We'll learn the very different paths they took to get here from Colorado and Texas – and what has kept them in La Jolla for so long. Janna and Tean also weigh in on why the alumni for fencing remain so engaged with the program. Plus, these two will be on the hot seat in the return of our popular Quick Picks segment. As always, host Jeff Tourial provides an update in other goings-on at UC San Diego in the Campus Spotlight. If you enjoy this week's show, please subscribe, rate, and write a brief review on your podcast platform of choice. Listen to past episodes anytime on-demand at ucsdtritons.com/podcasts. For show updates, follow @Tritoncast on X. Go Tritons!

Mara De Luca's (b. 1973, Washington D.C.) paintings evoke a sense of atmospheric abstractions that bring to mind dusk, sunsets, and planetary orbs. Throughout her work there is a sense of reflected ambient light. De Luca's work today extends the celebration of illusionism, romanticism, and the sublime with a deeply informed response to modernist painting. De Luca received an MFA from CalArts, Los Angeles, CA and a BA from Columbia University, NY. Her work has been displayed at the Museum of Contemporary Art, San Diego and is in prominent collections, including the Buck Collection at UC Irvine, JP Morgan Chase, New York; Fidelity, Boston; Alexander Plaza Berlin, Germany; New York Medical College, New York; and the University of Oslo, Norway. She has been reviewed in Artforum, Cultured Magazine, The Los Angeles Times, Artweek LA, and others. De Luca is a recipient of the 2019 California Community Foundation Fellowship for Visual Artists. She has taught Painting at UC San Diego, UC Irvine, UC Davis and UC Riverside. Based in Los Angeles for over two decades, De Luca now lives and works in New York. Mara De Luca, Western Gate 1, 2024 mixed media on canvas with copper plated element 54 × 96 inches (137 × 244 cm) Mara De Luca, Western Gate 2, 2024 acrylic on primed and unprimed canvas with brass plated element 59 x 132 inches (150 x 335.5 cm) Mara De Luca, Cut Western Clouds, 2024, mixed media on cut canvas with copper plated elements, 48 x 42 x 3 inches (122 x 106.5 x 7.5 cm).

A more permanent fix is coming to the San Diego-Los Angeles rail corridor plagued by coastal erosion. Plus, how are San Diego County farmers impacted by the Trump administration's back and forth tariff policy. And, a psychiatry professor at UC San Diego says a meditation-based therapy is shown to be effective in reducing chronic pain and lowering the use of opioid medication.

Tokeli Baker is a multidimensional artist who works across various creative fields, including painting, music composition, theatre, and writing. She has a background in musical theatre and dramatic literature, having studied at UC San Diego and Tufts University. Her artistic journey took a profound turn after experiencing a paranormal psi phenomenon following a traumatic accident, which led her to explore themes of consciousness and meditation in her work.She is also involved in the Escondido Art Association, serving as Co-President, and has exhibited her work in various venues, including the Poway Center for the Arts. One of her notable pieces, the "Intelligence" mural, is part of a series called "The Orbs," which visually represents meditative states beyond space-time.If you're interested in learning more about her work, you can visit her official website down below.Tokeli's Website:https://www.tokeli.com/Escondido Art Association Websitehttps://www.escondidoartassociation.com/Want a video experience? Check out our YouTube channel! We're now uploading video episodes!This episode:https://youtu.be/o4eaPh42b9cGeneral channel:http://www.youtube.com/@intheartscene

We often talk about providing not just jobs, but decent jobs, in developing countries. But in many parts of the world, workers still have incredibly harsh working conditions. There have been interventions at the firm level to create safer workplaces, better health, higher job satisfaction. But have they succeeded? And, if these policies succeed in raising worker well-being, is there a cost or a benefit for the employer? In the latest in our collaborations with J-PAL to discuss their policy insights, Achyuta Adhvaryu, UC San Diego about their review of the research into worker well-being, the policies that encourage firms to improve it, and the outcomes for employees and employers alike. You can find the review here https://www.povertyactionlab.org/

The seemingly outsized strength of cold-formed steel is not well-known. In this episode, earthquake engineer Ben Schafer, Johns Hopkins University, describes a research-industry collaboration with the automotive industry resulting in code changes for high-strength sheet-steel. Sheet steel has also been successfully tested in flooring systems. The upcoming CFS10 shake table test at UC San Diego is the high-rise building test for cold-formed steel. Schafer addresses misconceptions that structural engineers have regarding CFS: Basically: cold-formed steel looks too thin to be strong. However, with high-strength sheet steel, deformations do not correlate to lack of strength, which is something that automotive and aircraft engineers have long understood.

Franchises, reboots, crossovers, live-action remakes, interpolations… Why does the entertainment industry keep churning out cultural products that are derivative of something that came before, like Nicki Minaj rapping over “Barbie Girl” at the end of the Barbie movie on an endless loop?According to Andrew DeWaard, a professor of media and popular culture at UC San Diego, it's because of Wall Street. In his brain-expanding new book, Derivative Media: How Wall Street Devours Culture, Andrew pulls back the curtain on how popular culture has become derivative in a deeper, more insidious way: it's private equity buying up entire song catalogs, activist hedge funds staging hostile takeovers of entertainment conglomerates, and the cultural industries getting consumed wholesale by the financial sector — actual derivatives trading included.That wave of financialization is having an increasingly palpable effect on what we see and hear when we open up apps like Spotify and Netflix — not just in terms of the kinds of works that get funded, but increasingly, in the character of the works themselves, leading Andrew to posit that “the stock exchange has become embedded within the media text.”Andrew joins us to talk about how finance-world strategies impact both the companies that fund the culture we consume and the labor of those who produce it — and how they result in an entertainment landscape that is increasingly inhospitable to taking big risks. And we get into how the logic of the derivative has become embedded in media products themselves, from Jay Z turning lyrical wordplay into a champagne empire, to the White Lotus casting K-pop star LISA.Want to continue the conversation? For access to our member-only Discord (and all our bonus episodes), sign up for a paid subscription.Order a copy of Derivative Media — or download an open-access PDF for free.Read more by Andrew:The Cinema of Steven Soderbergh: Indie Sex, Corporate Lies, and Digital Videotape (Columbia University Press)“Independent Canadian Music in the Streaming Age: The Sound from above (Critical Political Economy) and below (Ethnography of Musicians)” (Popular Music and Society) This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit theculturejournalist.substack.com/subscribe

In this episode, Dr. Seema Khosla explores the critical issue of clinician burnout with Dr. Venktesh Ramnath, Associate Clinical Professor at UC San Diego. Moving beyond typical wellness advice, Dr. Ramnath offers practical strategies for addressing burnout at its systemic roots rather than treating it as an individual failure.  The conversation examines how to recognize true burnout versus temporary fatigue and challenges the common rhetoric about "resilience" that shifts responsibility from broken systems to individuals. Dr. Ramnath shares his personal burnout experience and discusses whether dramatic career changes are necessary before making meaningful improvements to professional satisfaction.  Discover actionable steps for reducing burnout, including negotiating with leadership, establishing horizontal professional networks, and eliminating low-value work. Learn how coding efficiency relates to burnout and understand the emerging role of "health architects" in creating sustainable medical workplaces.  The discussion also addresses Dr. Ramnath's public response to demands for federal employee productivity reporting, techniques for constructive workplace conversations, and practical advice for saying "no" effectively—a crucial skill rarely taught in medical training. Whether considering a job change or trying to improve a current position, this episode provides essential guidance for creating a more sustainable medical career. 

The global economy and U.S. markets have been reeling since President Trump announced a sweeping package of tariffs on Wednesday. China retaliated late Friday with a matching tariff, further nosediving the stock market and escalating the trade war. Economists predict the expansive tariffs will raise prices and impact jobs, and potentially lead to a recession and upend the global economy. We'll talk to experts about why markets are reacting the way they are, and what it might mean for the future of the global economy. Guests: Stephanie Flanders, senior executive editor, Bloomberg; head of Bloomberg Economics Lori Wallach, director, Rethink Trade program at American Economic Liberties Project; senior advisor; Citizens Trade Campaign Kyle Handley, associate professor of economics, School of Global Policy and Strategy, UC San Diego; director, Center for Commerce and Diplomacy Learn more about your ad choices. Visit megaphone.fm/adchoices